StockStory Favors Eli Lilly and Moody’s, Questions Nordson
The publisher cited revenue growth and other measures for its two favored stocks, while pointing to weaker growth and returns at Nordson.
Key takeaways
- StockStory highlighted Eli Lilly’s 43.1% annual revenue growth over the past two years.
- The publisher cited Moody’s 11.6% annual sales growth over the same period.
- StockStory pointed to Nordson’s anticipated 6.4% sales growth next year as a concern.
StockStory named Eli Lilly and Moody’s as stocks it believes could deliver good returns over the long term, while describing Nordson as risky. Its assessment cited growth, profitability and shareholder-return measures for the three S&P 500 companies.
For Nordson, StockStory pointed to organic revenue growth that fell short of its benchmarks over the past two years. It also cited anticipated sales growth of 6.4% next year and waning returns on capital as reasons for concern.
The publisher’s case for Eli Lilly included 43.1% annual revenue growth over the past two years and an 18.7-percentage-point expansion in adjusted operating margin. It also said share buybacks helped earnings per share grow faster than revenue over the past five years.
StockStory cited Moody’s annual sales growth of 11.6% over the past two years, along with annual earnings-per-share growth of 21.3%. It also pointed to the company’s 59.9% return on equity.
The article listed forward price-to-earnings ratios of 25.8 for Nordson, 29.3 for Eli Lilly and 25.9 for Moody’s. These figures accompanied StockStory’s assessment of each company, rather than a guarantee of future performance.
This article was produced with the help of AI technology. Source: Yahoo Finance
